Quantum Technology - IonQ announced an $1.8 billion acquisition of SkyWater Technology to accelerate its roadmap towards fault-tolerant quantum computing, with plans to start functionality testing of 200,000 qubit QPUs by 2028 [6][8] - A Chinese research team discovered new principles in quantum systems using the 78-qubit superconducting quantum processor "Zhuangzi No. 2," which enhances the application of quantum computing in fields like financial modeling and drug development [7][9] Biomanufacturing - Kangnuo Biopharmaceutical submitted an application for listing on the Hong Kong Stock Exchange, focusing on mitochondrial medicine and NAD+ applications, with projected revenues of 303 million yuan in 2023 [10][11] - Guangdong Province released an action plan aiming for a 40% self-sufficiency rate in core strains of biomanufacturing by 2027, with a total output value exceeding 500 billion yuan [11] Hydrogen Energy and Nuclear Fusion - Sichuan Fusion New Energy Industry Investment Development Co., Ltd. officially commenced operations, supporting the construction of China's first internationally recognized fusion city [13] - CIMC Anrui announced the successful launch of China's first IV-type hydrogen gas bundle container, marking a significant advancement in domestic hydrogen storage and transportation technology [14] - Mingyang Electric and global leaders in hydrogen equipment established Guangdong Mingnuo Hydrogen Technology Co., focusing on high-end hydrogen equipment production [15] Brain-Computer Interface - Neuralink reported 21 participants in its human trials, with plans to enhance device performance by three times and introduce "blindsight" technology for the visually impaired by late 2026 [23][24] - The National Medical Products Administration in China is advancing the establishment of industry standards for brain-computer interface medical devices [28] Embodied Intelligence - Ant Group's Lingbo Technology open-sourced the LingBot-Depth model, significantly lowering development barriers in the industry and enhancing its competitive edge [31][32] 6G and Commercial Aerospace - CASIC successfully conducted a 120 Gbps laser communication experiment, doubling the previous rate and laying the groundwork for high-speed data transmission in commercial aerospace [33][34] - China plans to expand its "Space+" future industries, focusing on space infrastructure, resource development, and space tourism [36] Future Industry Catalysts - Key milestones for future industries in 2026 include significant events in quantum technology, biomanufacturing, hydrogen energy, brain-computer interfaces, embodied intelligence, and 6G [37][38]

Group 1 - The core viewpoint of the news is that 麦澜德 experienced a decline in stock price and has significant financing activities, indicating a high level of market interest and potential volatility [1] - As of January 26, 麦澜德's stock price fell by 3.09%, with a trading volume of 95.12 million yuan, and a net financing purchase of 1.08 million yuan [1] - The total financing and securities balance for 麦澜德 reached 125 million yuan, with a financing balance of 124 million yuan, accounting for 7.41% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, 麦澜德 had 6,402 shareholders, an increase of 17.23%, while the average circulating shares per person decreased by 14.70% [2] - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, a year-on-year increase of 4.01%, while the net profit attributable to shareholders was approximately 96 million yuan, a slight decrease of 0.07% [2] - 麦澜德 has distributed a total of 297 million yuan in dividends since its A-share listing, with 247 million yuan distributed over the past three years [3] Group 3 - As of September 30, 2025, among the top ten circulating shareholders of 麦澜德, 华夏稳增混合 (519029) ranked fourth with 701,500 shares, a decrease of 550,500 shares from the previous period [3] - Notably, 中信建投轮换混合A (003822), 中信建投甄选混合A (008347), and 汇添富成长焦点混合 (519068) have exited the list of top ten circulating shareholders [3]

每经AI快讯，有投资者在投资者互动平台提问：请问欧盟地区业务收入在公司整体营业收入中的占比 大致为多少？此外，公司对欧盟市场的销售主要通过哪种方式实现？是以境内主体直接向欧盟客户出口 为主，还是通过在欧盟国家设立的子公司进行销售，或通过第三方贸易商、代理商转销至欧盟市场？ 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 麦澜德（688273.SH）1月19日在投资者互动平台表示，目前欧盟地区业务收入较少，未对公司整体营 收构成重大影响，请广大投资者注意投资风险。公司对欧盟市场销售方式主要是通过欧盟境内经销商在 本地销售。 （记者 王晓波） ...

Group 1 - The core point of the news is that 麦澜德 experienced a decline of 5.05% in its stock price, reaching 49.09 yuan per share, with a trading volume of 168 million yuan and a turnover rate of 9.12%, resulting in a total market capitalization of 4.909 billion yuan [1] - 麦澜德 is a company based in Nanjing, Jiangsu Province, established on January 16, 2013, and listed on August 11, 2022. The company specializes in the research, development, production, sales, and services related to pelvic floor and postpartum rehabilitation products [1] - The main revenue composition of 麦澜德 includes pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1] Group 2 - 金元顺安基金 has a significant holding in 麦澜德, with its 金元顺安成长动力灵活配置混合 fund holding 20,000 shares, accounting for 2.88% of the fund's net value, making it the fifth-largest holding [2] - The fund has a total scale of 28.1676 million yuan, with a year-to-date return of 6.62%, ranking 2154 out of 8840 in its category, and a one-year return of 34.98%, ranking 3623 out of 8094 [2] - The fund manager, 孔祥鹏, has been in position for 8 years and 204 days, with a total asset scale of 143 million yuan, while the other manager, 韩辰尧, has been in position for 2 years and 322 days, managing 873 million yuan [3]

Summary of the Conference Call for MylanDe Company Company Overview - MylanDe Company focuses on brain-computer interface (BCI) products, targeting hospitals with pricing between 500,000 to 1,000,000 yuan at the hospital terminal, with discounts for distributors [2][3] - The company plans to enter 40 to 50 hospitals by 2026, with a sales target of over 10 million yuan in the first year for new products [2][6] Industry Insights - The pricing for BCI devices is approximately 900 yuan per session, with significant support from medical insurance, although specific reimbursement ratios are not yet clear [2][5] - The company is strategically positioned in the non-invasive BCI market, focusing on cognitive, motor rehabilitation, and closed-loop neural regulation [2][12] Core Technology and R&D - MylanDe's core technology is multimodal, integrating EEG and near-infrared technologies, developed in collaboration with Zhejiang University to enhance data accuracy and treatment efficacy [2][10] - The company invests several million yuan annually in R&D, with a commitment of over 100 million yuan for BCI projects, including a partnership with Jiangsu Province BCI Research Institute [4][13] Market Strategy - The company has established a sales team that includes existing rehabilitation and medical business teams, with plans to expand into new channels such as neurology and mental rehabilitation [5][14] - MylanDe aims to maintain a competitive edge with a six-month lead in the market and plans to introduce iterative products to solidify its market position [8][11] Product Development and Future Plans - MylanDe is focused on obtaining regulatory certifications for BCI products in cognitive and motor rehabilitation by 2027, with additional products expected by 2028 [12][20] - The anticipated gross margin for new products is between 75% to 80%, with expectations of significant profit contributions as sales scale up [21] Competitive Landscape - The company has a competitive advantage in the non-invasive BCI sector, with a focus on neural regulation, and is exploring partnerships for further development in the rehabilitation space [8][16] - MylanDe is also considering the potential for semi-invasive or invasive BCI technologies in the future [20] Financial Projections - The company expects growth in its pelvic floor and anti-aging product lines, with projected growth rates of approximately 10% for pelvic floor products and 10%-20% for anti-aging products in 2026 [28] Additional Insights - MylanDe is actively seeking domestic alternatives for imported components to stabilize its supply chain and reduce dependency [18][19] - The company is exploring the consumer market (To C) in the long term, with plans to expand applications beyond medical uses [22] - AI integration in medical applications is a focus area, with ongoing development of personalized treatment plans and a database for BCI data [24]

Macroeconomic Insights - December CPI year-on-year growth expanded, primarily due to a low base and rising food prices[8] - PPI year-on-year decline narrowed, influenced by rising non-ferrous metal prices and the ongoing effects of "anti-involution" policies[8] - The price environment may continue to improve in 2026, with PPI supported by deepening "anti-involution" policies and tightening competition for key minerals[8] Market Trends - In December, the top 100 real estate companies achieved a total sales amount of CNY 341.5 billion, a month-on-month increase of 39.7%[33] - For the full year 2025, the cumulative sales amount for the top 100 real estate companies was CNY 3.36 trillion, a year-on-year decrease of 19.8%[33] - The new stock market saw 18 new listings in December, raising over CNY 30 billion, with average first-day gains of 214% for the main board and 296% for the dual innovation board[18] Industry Performance - The credit bond issuance volume increased seasonally, with a total of 332 bonds issued, amounting to CNY 312.27 billion, a week-on-week increase of 306%[22] - The domestic electrolytic aluminum price reached CNY 23,300 per ton, the highest since March 2022, with the aluminum-to-copper price ratio hitting a 20-year high[42] - The solid-state battery industry is entering a new phase of industrialization, with expectations for mass production by 2026-2027[47]

Group 1 - Institutional investors have shown interest in 41 stocks this week, with 6 stocks receiving target prices [1] - Kelu Electronics received an "Outperform" rating from Guosen Securities, with a target price of 9.70 to 10.10 CNY, while the latest closing price was 8.13 CNY [1] - Lepu Medical was rated "Overweight" by Guojin Securities, with a target price of 21.00 CNY, and the latest closing price was 19.45 CNY [1] Group 2 - Mcland received a "Buy" rating from Everbright Securities, with a target price of 56.65 CNY, and the latest closing price was 53.24 CNY [1] - Other stocks such as China Merchants Bank, Weidao Nano, and Zhongtong Bus also received initial attention from institutions this week [1]

Industry Overview - Brain-Computer Interface (BCI) is a new cross-disciplinary technology that creates a communication channel between the brain and external devices, enabling direct information exchange [6] - BCIs can be classified into three types: invasive, semi-invasive, and non-invasive, with applications in medical rehabilitation, consumer interactions, and military fields [7] - The global BCI market is projected to reach $7.63 billion by 2029, growing from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% from 2019 to 2023 [13][14] - Over 1,500 financing events in the global BCI sector have raised nearly $10 billion, with significant investments in both the U.S. and China [16] Policy Guidance - Major countries have launched brain initiatives to support BCI development, with the U.S. investing approximately $4.5 billion in its BRAIN Initiative since 2013 [37][40] - China has initiated its "Brain Science and Brain-Like Intelligence Technology" project, with funding expected to reach hundreds of billions of yuan [39][42] Clinical Situation - The medical demand for BCIs is driven by the need for rehabilitation in stroke and disabled populations, with significant clinical research already underway for various diseases [3][33] - Clinical trials for BCIs are accelerating globally, with a rapid increase in the number of trials in China [3][11] Industry Progress - Notable advancements include Neuralink's implantation of over 10 devices and Synchron's achievement of brain-controlled iPad functionality [4][4] - Key overseas companies like Neuralink and Synchron are leading in the invasive BCI field, focusing on treatment and human-computer interaction [4][4] - Domestic companies are also making strides, with clinical trials accelerating and real-time Chinese language decoding being achieved [4][4] Industry Chain Analysis - The BCI industry chain consists of upstream hardware and software supply, midstream BCI product supply, and downstream applications in various fields [18] - Upstream technology innovation barriers are high, with breakthroughs in flexible electrodes and chips being critical [20][21] - Downstream applications are primarily in the medical field, which is the most mature area for commercialization [30]

Industry Research - The solid-state battery industry is entering a new phase, with consensus on mass production validation by 2026-2027, driven by multiple catalysts. The divergence lies in the process routes and pilot verification, as well as the ability to achieve a commercial closed loop by 2030. The assessment of technology and manufacturing maturity indicates that solid-state technology will progress from stages 5-6 to 7-8. The mid-term focus is on equipment and key materials, while the long-term shift will be towards leading solid-state companies and material companies with core patents [4]. PCB Equipment - The demand for AI computing power is driving a wave of capital expenditure in the PCB industry, with domestic PCB equipment manufacturers expected to see sustained order growth. The industry outlook remains positive, with NVIDIA's Rubin architecture potentially reshaping the demand and landscape for drilling equipment and needles [6]. Company Analysis - Meilan De (688273.SH) has been a leader in the domestic pelvic floor dysfunction (PFD) market for over a decade, focusing on pelvic and obstetric rehabilitation equipment. The company is expanding into reproductive anti-aging, sports rehabilitation, light medical beauty, and brain-machine interface fields, rapidly building a product matrix for women's health throughout their life cycle through self-research and acquisitions. The company utilizes various energy source technologies, including ultrasound, laser, electrophysiology, electrical stimulation, magnetic stimulation, and high-frequency, continuously leading industry development [6]. - Shuanglin Co. (300100.SZ) has been deeply involved in the automotive parts industry for 40 years, gradually forming industrial advantages through internal improvements and external acquisitions. The equipment and screw rod business are expected to become new growth drivers for the company. The outlook for the second half of 2026 is positive, with expectations for gradual increases in robot deployment and trends towards domestic screw rod replacement. Shuanglin possesses unique advantages in screw rod grinding equipment and processes, making it a rare player in the domestic screw rod field [8].

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2025年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规 则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等有关法 律、法规的规定，南京证券股份有限公司（以下简称"保荐机构"或"南京证券"）作 为正在履行南京麦澜德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）持续 督导工作的保荐机构，对公司2025年1月1日至本次现场检查期间（以下简称"本持续 督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 南京证券股份有限公司 （二）保荐代表人 李建勤、张红 （三）现场检查时间 2025年12月29日至2025年12月31日 （四）现场检查人员 张红、刘姝含 （五）现场检查内容 公司治理和内部控制情况、信息披露情况、公司的独立性以及与控股股东、实 际控制人及其他关联方资金往来情况、募集资金使用情况、关联交易、对外担保、 重大对外投资情况、公司经营状况等。 （六）现场检查手段 1、与公司部分董事、高级管理人员进行访谈； 1 ...